About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Chicago | 17,609 Studies Near You | Clareo Health

Clinical Trials LocationsChicago

Clinical Trials in Chicago

Discover 17,609 clinical trials near Chicago, Illinois. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3681-3700 of 17,609 trials

TERMINATEDPhase 22.2 miles

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

NCT04697056

Efficacy and Safety of imsidolimab in Participants with Ichthyosis

Vanda Pharmaceuticals5 participantsStarted Jan 2021

Palo Alto, California, United States • New Haven, Connecticut, United States • Miami, Florida, United States +4 more locations

Active Not RecruitingPhase 22.2 miles

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Non-segmental Vitiligo

Vyne Therapeutics Inc.200 participantsStarted Jun 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +46 more locations

Find Trials by Condition in Chicago

Breast Cancerin Chicago Lung Cancerin Chicago Prostate Cancerin Chicago Colorectal Cancerin Chicago Melanomain Chicago Leukemiain Chicago Lymphomain Chicago Pancreatic Cancerin Chicago Ovarian Cancerin Chicago Brain Cancerin Chicago Diabetes

Data from ClinicalTrials.govTerms

TERMINATEDPhase 42.2 miles

Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients

NCT04216784

A common complication of the progression of cirrhosis is fluid retention (ascites, edema, or pleural effusion). Loop diuretics are the treatment of choice for fluid retention in cirrhotic patients; however, many of these patients demonstrate diuretic resistance, requiring higher doses of the diuretics to achieve adequate diuresis. The cause of this diuretic resistance is hypothesized to be secondary to hypoalbuminemia which has led some providers to give human albumin in combination with loop diuretics to increase intravascular volume and facilitate diuresis. However, this practice remains controversial because minimal data exists to support its efficacy. The purpose of this study is to compare the efficacy of diuretics alone versus diuretics in combination with albumin in cirrhotic patients presenting with fluid retention.

Cirrhosis, LiverVolume OverloadFluid Overload

Rush University Medical Center21 participantsStarted Dec 2019

Chicago, Illinois, United States

COMPLETEDPhase 22.2 miles

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

NCT04476017

The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive impairment (PD-MCI).

Parkinson DiseaseCognitive Dysfunction

Supernus Pharmaceuticals, Inc.18 participantsStarted Jul 2020

Long Beach, California, United States • Port Charlotte, Florida, United States • West Palm Beach, Florida, United States +1 more locations

COMPLETEDPhase 1/22.2 miles

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Super-refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.25 participantsStarted Mar 2014

Birmingham, Alabama, United States • Sarasota, Florida, United States • Chicago, Illinois, United States +14 more locations

COMPLETEDPhase 22.2 miles

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.

Huntington Disease

Supernus Pharmaceuticals, Inc.69 participantsStarted May 2022

Birmingham, Alabama, United States • Los Alamitos, California, United States • Englewood, Colorado, United States +11 more locations

COMPLETEDPhase 12.2 miles

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).

New Approaches to Neuroblastoma Therapy Consortium65 participantsStarted Sep 2017

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +10 more locations

RECRUITINGPhase 311 miles

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939

This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis.

SWOG Cancer Research Network338 participantsStarted Jul 2024

Derby, Connecticut, United States • Guilford, Connecticut, United States • Hartford, Connecticut, United States +32 more locations

COMPLETEDNA12 miles

Omnipod 5 System Compared to Pump Therapy

NCT05409131

Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or continue to use their personal insulin pump with the study provided continuous glucose monitoring system. Participants in France will be offered an optional extension of 12 months of Omnipod 5 System use.

Type 1 Diabetes

Insulet Corporation196 participantsStarted Jul 2022

Palo Alto, California, United States • Santa Barbara, California, United States • Denver, Colorado, United States +11 more locations

Active Not RecruitingPhase 241 miles

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

ObesityOverweightChronic Weight Management

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics82 participantsStarted Dec 2024

Glendale, California, United States • Montclair, California, United States • Valparaiso, Indiana, United States +7 more locations

Active Not Recruiting125 miles

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

NCT05991323

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Prurigo Nodularis

Sanofi100 participantsStarted Dec 2023

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Fremont, California, United States +46 more locations

RECRUITING201 miles

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

NCT06104969

This study is a platform study designed to efficiently test multiple biomarkers to identify diabetic foot ulcers (DFUs) with a higher potential for healing versus not healing that ultimately could be applied at the point of care to drive personalized management decisions, and to better inform clinical trials of wound healing interventions

Diabetic Foot UlcerDiabetic FootDiabetes

University of Michigan5,000 participantsStarted Jun 2023

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +5 more locations

COMPLETEDNA202 miles

Veterans Response to Dosage in Chiropractic Therapy

NCT04087291

This study evaluates how Veterans with chronic low back pain (cLBP) respond to varying doses of chiropractic therapy and how health services utilization are impacted as a result. There are 2 phases in this study. In Phase 1, half of participants will receive a low dose (1-5 visits) of chiropractic care for 10 weeks, while the other half will receive a higher dose (8-12 visits) for 10 weeks. At the end of Phase 1, participants in each group will be randomized again to receive either chronic chiropractic pain management (CCPM) (1 scheduled chiropractic visit per month x 10 months) or no CCPM for 10 months.

Low Back PainPatient Acceptance of Health CareVeterans Health

Palmer College of Chiropractic766 participantsStarted Feb 2021

Los Angeles, California, United States • West Haven, Connecticut, United States • Iowa City, Iowa, United States +1 more locations

Active Not RecruitingPhase 2/3202 miles

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

NCT05397665

This study is designed to assess the efficacy and safety of AT-007 treatment in patients with SORD Deficiency. This randomized, double-blind study will assess the effect of AT-007 compared to Placebo in SORD Deficiency in patients for up to 24 months.

Hereditary Neuropathy Caused by SORD Deficiency

Applied Therapeutics, Inc.56 participantsStarted Jan 2022

Aurora, Colorado, United States • Coral Gables, Florida, United States • Iowa City, Iowa, United States +7 more locations

COMPLETEDNA231 miles

Device for Improving Skin Quality and Texture on the Face and Neck

NCT06645366

The goal of this clinical trial is to investigate the effect of the BTL-785F device (with BTL-785-4-4 tip on BTL-785-4 applicator) on the improvement of skin quality and texture on the face and neck in healthy adult volunteers. The main question it aims to answer is: Whether the BTL-785F device (with BTL-785-4-4 tip on BTL-785-4 applicator) is able to improve skin quality 3 months post-treatment, as assessed by two-dimensional and three-dimensional photographs. Participants will complete three treatments, and two follow-up visits.

WrinklePigmentationSkin Laxity+1 more

BTL Industries Ltd.39 participantsStarted Jun 2024

Greenwood Village, Colorado, United States • Chevy Chase, Maryland, United States • Birmingham, Michigan, United States

Active Not RecruitingNA237 miles

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

NCT00819208

RATIONALE: Participating in a physical activity program designed to increase free time physical activity and receiving written health education materials may influence the chance of cancer recurring as well as impact on physical fitness, psychological well-being and the quality of life of patients who have undergone surgery and chemotherapy for colon cancer. It is not yet known whether giving a physical activity program together with health education materials is more effective than giving health education materials alone for patients who have undergone colon cancer treatment. PURPOSE: This randomized phase III trial is studying a physical activity program given together with health education materials to see how well it works compared with giving health education materials alone for patients who have undergone treatment for high-risk stage II or stage III colon cancer.

Anxiety DisorderCognitive/Functional EffectsColorectal Cancer+5 more

Canadian Cancer Trials Group889 participantsStarted Jun 2009

Detroit, Michigan, United States • Lebanon, New Hampshire, United States • Chapel Hill, North Carolina, United States +44 more locations

COMPLETED251 miles

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

NCT05675371

The goal of this clinical study is to learn about the utility and performance of the EarliPoint(™) System: Evaluation for Autism Spectrum Disorder to monitor changes in a child's verbal ability, non-verbal learning, and social disability over time in children ages 15-84 months with autism spectrum disorder or related developmental delays (DD) and in those who are typically developing. The main questions it aims to answer are: * To estimate the change in each of the EarliPoint index scores in typically developing children ages 15-84 months from baseline through 180 days as a function of the child's age. * To estimate the change in the EarliPoint verbal and non-verbal index scores in ASD/DD children ages 15-84 months from baseline through 180 days as a function of the child's age in: a) those who showed clinical improvement, and b) those who did not show clinical improvement. * To estimate the relationship of the EarliPoint verbal and non-verbal index scores to clinical reference assessments in ASD/DD children as a function of their age from baseline through 180 days. * To estimate the degree of change, if change occurs, month-to-month in the EarliPoint Social Disability Index score from baseline through 180 days. * To estimate the incidence of behavioral events (e.g., tantrums, etc.) which limit the subject from completing an eye-tracking session. * To estimate the incidence of adverse device effects associated with the use of the study device.

Autism Spectrum DisorderAutismDevelopmental Delay+2 more

EarliTec Diagnostics, Inc325 participantsStarted Mar 2023

Phoenix, Arizona, United States • Glendale, California, United States • San Rafael, California, United States +6 more locations

COMPLETEDPhase 1/2276 miles

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

NCT03878199

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Giving ruxolitinib and CPX-351 may work better in treating patients with secondary acute myeloid leukemia compared to CPX-351 alone.

Essential ThrombocythemiaMyelofibrosisMyeloproliferative Neoplasm+2 more

Ohio State University Comprehensive Cancer Center12 participantsStarted Feb 2019

Columbus, Ohio, United States • Portland, Oregon, United States • Dallas, Texas, United States

Active Not Recruiting355 miles

Assessing the Time Demands of Cancer

NCT05708703

A total of 80 individuals receiving treatment for metastatic breast or advanced stage ovarian cancer will be asked to complete a baseline survey and install the mobile app on their smartphone; carry the smartphone for 28 consecutive days while outside the home; keep smartphone location and motion services active; confirm and correct (if needed) smartphone-detected activities and trips; use the app interface to provide additional information on activities and trips related to cancer treatment tasks; complete daily surveys regarding well-being; and at the end of the 28 day period, complete an online survey.

Metastatic Breast CancerOvarian Cancer

Masonic Cancer Center, University of Minnesota78 participantsStarted Nov 2023

Birmingham, Alabama, United States • Minneapolis, Minnesota, United States

RECRUITINGPhase 1/2409 miles

Promising ROd-cone DYstrophy Gene therapY

NCT05748873

This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.

Retinitis Pigmentosa

SparingVision33 participantsStarted Apr 2023

Miami, Florida, United States • Boston, Massachusetts, United States • Portland, Oregon, United States +3 more locations

PreviousPage 185 of 881Next

in Chicago

Heart Diseasein Chicago